Bioline Rx Ltd - ADR
BLRX
Get informed when a big investor buys or sells
+ FollowMarket Cap$11.31M
Close$
$-2.48
190.5% downside
Current Fair Value
190.5% downsideOvervalued by 190.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $11.31 Million |
|---|---|
| Enterprise Value | $17.88 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.29 |
| Beta | 0.71 |
| Outstanding Shares | 4,433,715 |
Return
| Return on Equity | -43.28% |
|---|---|
| Return on Assets | -18.60% |
| Return on Invested Capital | -1.81% |
Valuation & Multiples
| P/E Ratio | -1.4 |
|---|---|
| PEG | 0.93 |
| Price to Sales | 2.74 |
| Price to Book Ratio | 0.69 |
| Enterprise Value to Revenue | 2.99 |
| Enterprise Value to EBIT | -39.3 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.51 |
| Debt to Equity | 0.54 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 31, 2026
EPS Estimate
$-0.15
Average shareholder expectationRevenue Estimate
$500,000
Average shareholder expectationNext Earnings Call
Expected Date
November 18, 2026
EPS Estimate
$-0.09
Average shareholder expectationRevenue Estimate
$375,000
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 103.45% |
|---|---|
| Total Calls | 10,200▼ 12.07% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.44%▼ 0.66% |
|---|---|
| Total Invested | $45,224▼ 66.66% |
| Investors Holding | 13▼ 2.00% |
ESG Score
No data
About Bioline Rx Ltd
CEO: Philip Serlin